BNET Industries
Market Cap:$14.6B
Last Fiscal Year Sales:$15.6B
- Public
- NL
Dow Jones Description
Akzo Nobel's paint colors turn the competition green. Founded in 1911 and headquartered in Arnhem, Netherlands, Akzo Nobel N.V. (NASDAQ: AKZOY (ADR); AMS: AKZA) is the world's largest paint maker, among other businesses. The company operates in several segments. Coatings segment produces paints, stains, chemicals, auto finishes, and synthetic resins. Pharmaceuticals segment produces prescription and over-the-counter drugs. Chemicals segment produces specialty, functional, and commodity chemicals. The company has annual revenue of about ?13 billion and employs about 61,500 people. Akzo Nobel was listed on FTSE4Good Index in 2006. In 2005 it was selected as a member of the prestigious Dow Jones Sustainability Indexes, World and Stoxx.
Chairman & CEO
G.J. WijersNumber of Employees 42,600
Peer Companies
NAICS Code Medicinal and Botanical Manufacturing: 325411
Recent Events
-
2nd UPDATE: Akzo 3Q Net Profit Up, Fiscal Year Outlook Missing
-
UPDATE: AkzoNobel 3Q Net Profit Up 30%, No Full-Year Outlook Given
-
Kemira to buy Akzo Nobel's iron coagulant business in Nordic countries
-
BRIEF-RESEARCH ALERT-Goldman cuts Givaudan to sell; raises Syngenta, DSM to buy
-
Akzo profit a sign chemical makers have potential to surprise
-
2nd UPDATE: AkzoNobel 2Q Net 13% Down, No Fiscal Year Outlook Given
-
Akzo Nobel reports 13% decline in 2Q net income to Euro 155 million for 2009
News & Analysis
Filter by
akzo nobel n.v. and clariant corp. - All News and Analysis
Fined for price fixing
The European Commission has fined three European chemical companies a total of 217m [euro] ($285m) for conspiring to fix prices of monochloroacetic acid. The companies--Akzo Nobel, Hoechst and Atofina now Arkema--ran a cartel from 1984 until 1998 in collusion with Swiss chemicals firm Clariant. Akzo was fined 84m [euro], Hoechst...
A time of change for custom manufacturing/fine chemicals. (Focus 2003: Fine Chemicals Leaders: CEOs and Companies).
Reorganizations, restructuring and modest investments top the agenda of some of the leading custom manufacturers/fine chemical producers. As custom manufacturers/fine chemical producers wait for improvement in drug output, several companies will wait to see whether recently shifted organizations, restructured operations and...
No relief for Europe's specialties giants. (Top of the Week).(specialty chemicals industry shows weak earnings)(Industry Overview)
Several of Europe's leading specialty chemicals firms have reported surprisingly weak 2002 earnings, and hopes are fading for a quick recovery table. Sales and profits have been undermined by high oil prices, the weakness of the dollar, and increased pension liabilities due to falling stock markets,...
Slowdown in pharma sales lowers fiscal returns. (News: Europe).
EUROPEAN CHEMICAL majors Clariant, Akzo Nobel and DSM saw revenues slip in 2002, and, for Clariant and Akzo Nobel, margins were hit hard by disappointing performances in their life sciences segments. Clariant posted a net loss of SFr 648 million ($473 million)...
Product listings. (A. Chemical Specialties-E. Solvents).
RAW MATERIALS A. CHEMICAL SPECIALTIES ABRASIVES, ANTI SKID POLYMERIC American Fillers & Abrasives The Chemical Co. * Daicolor-Pope, Inc. Daubert Chemical Co., Inc. Electro Abrasives GE...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| R.J. Frohn | CFO |
| Rob Frohn | CFO |
| Keith Nichols | Senior Vice President, Finance |
| O. Werner | Senior Vice President, HR |
| Jan H. Dopper | Technology Director |
| John McLaren | Director, Corp Communications |
| M. Rooseboom | Senior Group Director, Coatings |
| Barry Oonk | Manager, Advertising |
| Bill McPherson | General Manager, Marine & Protective Coatings |
| Rob Molenaar | General Manager, Powder Coatings Business |
| A. Jan Eijsbouts | General Counsel |
| A.T.M. Wilderbeek | Member, Management Bd, Pharma |
| Han Jalink | Secretary |
| Leif Darner | Head |
| Rudy M.J. van der Meer | Member, Management Bd, Coatings |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| G.J. Wijers | Chairman & CEO |
| Antony Burgmans | Supervisory Board |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Chairman & CEO | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | CFO | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | CFO | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Senior Vice President, Finance | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Senior Vice President, HR | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Technology Director | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Director, Corp Communications | Current |
| Akzo Nobel N.V. | Director, Corp Communications | Former |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Senior Group Director, Coatings | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Manager, Advertising | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | General Manager, Marine & Protective Coatings | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | General Manager, Powder Coatings Business | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | General Counsel | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Member, Management Bd, Pharma | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Secretary | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Head | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Member, Management Bd, Coatings | Current |
| James Hardie Industries N.V. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Amoco Ultimate | Board of Directors | Current |
| Bp Alternative Energy | Board of Directors | Current |
| Air Bp Limited | Board of Directors | Current |
| Bp Refining and Petrochemical | Board of Directors | Current |
| Progas Limited | Board of Directors | Current |
| The Bp Group | Board of Directors | Current |
| Bp Solar Neighbors Program | Board of Directors | Current |
| Akzo Nobel N.V. | Supervisory Board | Current |
| Bp Solar International, Inc. | Board of Directors | Current |
| Bp Marine | Board of Directors | Current |
| AEGON N.V. | Supervisory Board | Current |
| BP plc | Board of Directors | Current |
| Wristore | Board of Directors | Current |
| Unilever N.V. | Business Group Vice President | Former |
| Unilever | Marketing Assistant | Former |
| Unilever N.V. | Chairman, Unilever Indonesia | Former |
| Unilever N.V. | Chairman | Former |
| Unilever N.V. | Vice Chairman | Former |
| Unilever Plc | Vice Chairman | Former |
| Unilever | Board of Directors | Former |
| University of Lancaster | MA | Former |
| Nijenrode University | Former | |
| University of Stockholm | Former |
| Volume | 11,474 |
| Shares Outstanding | 231.6M |
| Market Cap | 14.6B |
| Year High | 70.00 |
| Year Low | 32.15 |
| Earnings Per Share | -6.7840 |
| P/E Ratio | N/A |
| Dividend | 1.94 |
| Yield | 3.0698 |
Industry Transcripts by Seeking Alpha
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes


